(PRWEB) September 19, 2014
Vascular Health and Risk Management has published the study protocol “XANTUS: rationale and design of a noninterventional study of rivaroxabanfor the prevention of stroke in patients with atrial fibrillation”.
As corresponding author Professor Camm says “The phase III ROCKET AF clinical trial led to the approval of rivaroxaban for stroke prevention in patients with atrial fibrillation. However, patients and treatments in routine practice may differ from those in a clinical trial. The XANTUS study's objective is to address that gap and assess the safety profile of rivaroxaban in routine care.”
Professor Camm continues “XANTUS is a non-interventional study of 6000 patients for whom rivaroxaban therapy is chosen solely by the treating physician, and is carefully designed so that enrolled patients truly reflect the routine care population. The resulting dataset is expected to provide comprehensive support for the safety of rivaroxaban and important data on management of adverse events in routine care.”
Vascular Health and Risk Management is an international, peer-reviewed journal of therapeutics and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention, and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes.
Dove Medical Press Ltd is a privately held company specializing in the publication of Open Access peer-reviewed journals across the broad spectrum of science, technology and especially medicine.